Concepedia

Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases

Brian S. Gerstenberger, Catherine M. Ambler, Eric P. Arnold, Mary-Ellen Banker, Matthew F. Brown, James D. Clark, Alpay Dermenci, Martin E. Dowty, Andrew Fensome, Susan Fish,

Journal of Medicinal Chemistry · 2020 · 75 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

).

References

28

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Bruce E. Sands, William J. Sandborn, Remo Panaccione et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

, , +17

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine · 2017 · 511 citations · Full text

, , +16

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

Kim Papp, Kenneth B. Gordon, Diamant Thaçi et al. · New England Journal of Medicine · 2018 · 414 citations · Full text

, , +17

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2019 · 369 citations · Full text

, , +15

Development of a new permeability assay using low‐efflux MDCKII cells

Li Di, Carrie Whitney‐Pickett, John P. Umland et al. · Journal of Pharmaceutical Sciences · 2011 · 317 citations

, , +10